Agilent Technologies, Inc.

NYSE:A

Medical - Diagnostics & Research

Healthcare
$177.33 +2.44%

+$3.04 today

Market cap
$50.00B
Beta
1.26
P/E (TTM)
25.5
EPS (TTM)
$5.00
Dividend yield
0.59%
52W Low $108.35High $160.27

Volume 2.48M

Average 2.24M

A Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Agilent Technologies, Inc.NYSE: A

Cost of Revenue · Q3 FY2026 · quarter ended Jul 2026

Cost of revenue grows, but more slowly than its trailing trend

Q3 FY2026 cost of revenue of $836M rose 1.5% year over year, behind the +6.8% change in trailing-twelve-month cost of revenue. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at +1.9% a year.

Context

  • Cost of revenue amounted to 47.6% of revenue in FY2025, up 1.9 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +1.5% toward the trailing-twelve-month pace of +6.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJul 2026
$836M+1.2% QoQ
Last fiscal yearOct 2025
$3.31B+11.1% YoY
LTMJul 2026
$3.41B+6.8% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.5%——
1 year+11.1%——
3-year CAGR+1.9%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
3.31B USD
Year-over-year change
+11.1%
4-year CAGR
+3.2%

Cost of Revenue vs competitors

How A compares with its peers on the latest reported figures

  • A's LTM Jul 2026 cost of revenue of $3.41B is the 3rd highest of the 9 companies compared; the peer median is $1.79B.
  • Its year-over-year change of +6.8% is the 5th highest of 9, against a peer median of +7.0%.
  • Cost of revenue amounts to 46.3% of revenue for A, versus a peer median of 48.0%.
A Competitors Peer median
Cost of Revenue for A and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMOThermo Fisher Scientific Inc.LTM Sep 2026$27.73B +6.5%+0.5%58.6%
DHRDanaher CorporationLTM Sep 2026$10.6B +12.9%-2.8%41.4%
AAgilent Technologies, Inc.LTM Jul 2026$3.41B +6.8%+1.9%46.3%
WATWaters CorporationLTM Jul 2026$2.29B +83.1%+2.3%49.2%
BRKRBruker CorporationLTM Jun 2026$1.87B +4.7%+14.9%53.3%
MTDMettler-Toledo International Inc.LTM Jun 2026$1.72B +7.4%-0.8%41.6%
RVTYRevvity, Inc.LTM Jul 2026$1.39B +8.5%-4.8%47.9%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$1.25B +3.4%+0.1%48.1%
QGENQiagen N.V.LTM Jun 2026$801.85M +6.1%+1.8%38.2%
Peer median (excluding A) $1.79B+7.0%+0.3%48.0%

Competitors are the stored peer set for A. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Revenue6.32B6.85B6.83B6.51B6.95B
Cost of Revenue2.91B3.13B3.37B2.98B3.31B
Gross Profit3.41B3.72B3.47B3.54B3.64B
Gross Margin53.9%54.4%50.7%54.3%52.4%
Research & Development441M467M481M479M455M
Selling, General & Admin1.62B1.64B1.63B1.52B1.71B
Operating Expenses2.06B2.1B2.12B2.05B2.16B
Depreciation & Amortization321M317M271M257M288M
EBITDA1.76B1.91B1.7B1.87B1.84B
EBITDA Margin27.9%27.8%24.9%28.8%26.4%
Operating Income1.35B1.62B1.35B1.49B1.48B
Operating Margin21.3%23.6%19.8%22.9%21.3%
Interest Income2M9M51M80M62M
Interest Expense81M84M95M96M112M
Other Income / Expenses13M(114M)(11M)33M(44M)
Income Before Tax1.36B1.5B1.34B1.52B1.44B
Pre-Tax Margin21.5%22.0%19.6%23.4%20.7%
Income Tax Expense150M250M99M232M132M
Net Income1.21B1.25B1.24B1.29B1.3B
Net Margin19.1%18.3%18.1%19.8%18.8%
EPS (Basic)3.984.194.224.444.59
EPS (Diluted)3.944.184.194.434.57
Weighted Avg Shares304M299M294M290M283M
Weighted Avg Shares (Diluted)307M300M296M291M284M

Agilent Technologies, Inc.

NYSE:A

Intrinsic Alpha fair value

Locked

Current Price

$177.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.